Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK)

See why Cytokinetics, Incorporated's aficamten could become the first-line therapy for obstructive HCM, surpassing metoprolol and Camzyos. Click for my CYTK update.